Futility Analysis: Practical Considerations
View Presentation View Presentation
*Benjamin Trzaskoma, Genentech 


Given the non-trivial failure rate of phase III studies and a high bar for efficacy for future pipelines, we take a critical look at futility analyses and explore ways to more effectively utilize them in clinical trials. Through real examples, we examine the potential risk/benefit of futility analyses and raise points to consider for key stake holders.